Michael Boyer

Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials

Janette Vardy, Philip Beale, P. Beale, 2009, BMC Cancer.

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

Claude Denham, Salih Emri, Nicholas J Vogelzang, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements.

S. O'toole, L. Horvath, W. Cooper, 2011, Pathology.

An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer

Glen Reid, G. Reid, W. Cooper, 2018, Journal of clinical medicine.

Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

Victoria Keena, D. Henderson, A. Musk, 2013, Journal of thoracic disease.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Chun-Ming Tsai, Dan Massey, Nobuyuki Yamamoto, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gaps in Optimal Care for Lung Cancer

Dianne L. O’Connell, Bruce Armstrong, Danielle Miller, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.